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ABSTRACT 
Background. Pulmonary vein (PV) isolation is the cornerstone of catheter ablation in 
patients with atrial fibrillation (AF). “Single shot” ablation devices have been recently 
engineered.  
Objectives. We report on the safety and efficacy of a novel ablation catheter for PV 
isolation in patients with AF.  
Methods. One hundred-eighty consecutive patients (58±10 years, 125 males, 31% with 
structural heart disease) referred for paroxysmal (140) or persistent (40) AF underwent PV 
isolation by an open-irrigated mapping and radiofrequency (RF) decapolar ablation 
catheter in 7 centers. Ablation was guided by electroanatomic mapping allowing RF 
energy delivery in the antral region of PVs from 10 irrigated electrodes simultaneously.  
Results. Mean overall procedure time was 113±53 min with a mean fluoroscopy time of 
13.1±8.4 min. The use of a pre-ablation PV imaging related to a significant reduction in 
fluoroscopy time (from 14.7±9.7 to 8.7±6.6, p<0.001). Mean ablation time was 12.5±5.1 
min, 98% of the targeted veins were isolated with a mean of 23.4±6.3 RF pulses per 
patient. In only four (2.2%) patients a single point ablation strategy was required to achieve 
PV isolation. One groin hemathoma and one PV stenosis were reported. During a mean 
follow-up of 13.9 ± 8.2 months 38/140 (27%) patients with paroxysmal AF and 12/40 (30%) 
patients with persistent AF had an atrial arrhythmia relapse (p=0.671)  
Conclusions. In this multicenter registry, irrigated multi-electrode RF ablation resulted 
feasible, achieving a high rate of isolated PVs. Procedural and fluoroscopy times and 
success rates were comparable with other techniques with a low complication rate.  
KEYWORDS: Atrial fibrillation; Catheter ablation; Multielectrode ablation catheter; Safety; 
Mid-term outcome 
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INTRODUCTION 
Catheter ablation (CA) has become a well-established and widespread treatment 
for recurrent, symptomatic, drug-resistant atrial fibrillation (AF) (1,2). Although several 
approaches and techniques have been proposed, ablation strategies that target pulmonary 
veins (PVs) or PV antra are the cornerstone for most AF ablation procedures (3). When 
targeted, complete electrical PV isolation should be the goal, particularly when AF is 
paroxysmal, that is, when triggers play a predominant role. However the ablation 
procedure may still require long procedure and fluoroscopy time. Another week point of 
single-tip ablation catheter procedure is the deployment of a durable, contiguous 
transmural ablation line around the PVs. Reconnection of the PVs play a pivotal role in the 
mid- and long-term AF recurrences after CA. These limitations led to the development of 
single-shot devices (4-7) that allow delivery of different energy forms by anatomically 
designed ablation tools aimed at the creation of standardized linear lesions by only a few 
impulse applications. We report data from a multicenter registry on the acute safety and 
efficacy of a novel irrigated multielectrodes ablation catheter for PV isolation in patients 
with paroxysmal and persistent AF.  
 
METHODS 
Patients selection. This multicenter registry enrolled patients in 7 Italian centers (see the 
Appendix). Patients aged between 18 and 90 years with documented symptomatic 
paroxysmal or persistent AF episodes refractory to drug therapy (Class I or  III drugs). 
Exclusion criteria were: (1) long-standing persistent AF, defined as AF being the sole 
rhythm for >12 months before the enrolment; (2) previous CA of AF; (3) New York Heart 
Association functional class > II; (4) unstable angina or acute myocardial infarction within 
three months; (5) need for or prior cardiac surgery within six months; (6) contraindication 
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to treatment with oral anticoagulants or bleeding diathesis; and (7) severe chronic renal or 
hepatic impairment. In patients in which a pre-ablation left atrial/PV imaging (computed 
tomography or magnetic resonance scan) was available inclusion was not based on any 
anatomical characteristics. 
This study was approved by the institutional review committees, and all patients signed 
informed consents. The principle outlined in latest update of the Declaration of Helsinki 
were followed. 
Ablation procedure. Vascular access were obtained through one or two femoral veins, 
and in some patients one subclavian vein. A quadripolar or decapolar catheter was 
introduced into the coronary sinus. A transseptal access to the left atrium was achieved 
using standard approach. By placing a wire in the left superior PV, the fixed sheath was 
exchanged, in the majority of the cases, for a steerable sheath (8.5F AgilisTM St Jude 
Medical, or ZurpazTM,Boston Scientific) by using the Seldinger technique. Then, the 
nMARQTM (Biosense Webster Inc, Diamond Bar,CA) catheter was introduced into the 
steerable sheath. After transseptal access, an intravenous bolus of heparin (0.1–0.5 mg/kg 
of body weight according to INR) was administered and repeated if needed to maintain an 
activated clotting time > 320 s. The transseptal sheath was continuously flushed (200 
mL/h) with heparinized saline. 
Briefly, the nMARQTM is a steerable 8.4 F ablation and mapping 10-pole irrigated RF 
catheter with a novel irrigation design. Platinum electrodes are 3 mm long, with a spacing 
of 4 mm. Each of the electrodes retains a thermocouple and holes for irrigation. Each 3-
mm electrode is individually irrigated via 10 irrigation holes using a constant flush of 4 
mL/min during mapping and 60 mL/min flushing rate during ablation. By a steering 
mechanism placed at the handle, the catheter can be deflected unidirectionally. The 10 
electrodes are arranged in a nearly circular array and the diameter may be changed in 
between 35mm down to 20 mm. RF ablations were preset at 30-60 seconds duration in 
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temperature-controlled mode and energy delivery can be individually arranged over each 
combination of the 10 electrodes in unipolar mode (maximum 25 W and 45 ◦C) or bipolar 
mode over 2 adjacent electrodes (maximum 15W and 45 ◦C). The nMARQTM catheter was 
visualized in the CARTO3 system (Biosense Webster Inc, Diamond Bar,CA) and ablation 
was directed towards the antrum of each PV sequentially. Before ablation, the left atrial 
anatomy was acquired using the nMARQTM catheter or with the decapolar catheter 
previously placed in the coronary sinus (DecaNav, Biosense Webster Inc, Diamond 
Bar,CA). Maps were acquired during AF or sinus rhythm using respiratory gating. Fast 
anatomic mapping or imaging integration with a pre-acquired computed tomography or 
magnetic resonance scan was used, according to operators’ preference. Further 
information on wall contact was gained from an impedance based technology built into the 
EAMS (Tissue Connect, Biosense Webster Inc, Diamond Bar,CA). Electrodes not in 
contact were deactivated before the start of ablation. Ablations were performed usually via 
all 10 electrodes and increase in temperature, drop in local impedance, and energy 
delivery were continuously monitored using the novel nMARQTM Multi-Channel RF System 
ablation generator (Biosense Webster Inc, Diamond Bar,CA) capable of synchronously 
applying energy to all 10 nMARQTM electrodes. 
All ablations in our patient group ablations were usually performed in unipolar mode. After 
ablation the catheter was slightly rotated to ablate in potential gap regions only if 
electrograms were still identified. Electrodes were only deselected for ablation if no 
electrogram was visible on adjacent bipolar readings. In our patient cohort ablations were 
performed in a range between 20 and 25W over all applicable electrodes. Pacing for 
phrenic nerve capture was usually performed during right PVs isolation. Esophageal 
temperature monitoring was not routinely performed. However, a power limited to 15-20W 
was used for electrodes in contact with the posterior wall. Before ablation, electrograms 
templates were captured for each PV and after PV isolation abatement of electrograms 
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and PV potentials were controlled using the nMARQTM (Figure 1). In addition, PV high-
output pacing (10 V, 2.0 milliseconds) was performed to identify PV exit block if the 
nMARQTM was managed into the PV. Early PV reconnection was tested 30 minutes after 
PV isolation, or by means of adenosine infusion, for each PV using the nMARQTM catheter.  
The necessity of touch-up lesions using a conventional-irrigated-tip catheter 
(SmartTouchTM, Biosense Webster Inc. CA) was recorded in each patient. In cases, 
conventional ablation was performed with 30-35 W depending on the site of ablation. 
Procedures were performed either with continued oral anticoagulation using warfarin and 
therapeutic INR (2.0–2.5) or new oral anticoagulants or using low-molecular weight 
heparin bridging.  
Postablation management and follow-up.  Oral anticoagulation was continued the same 
day for all patients and administered for at least 3 months and with no time limit in patients 
with a CHA2DS2-VASC score ≥ 2. Antiarrhythmic drugs were usually discontinued ≥5 half-
lives prior to ablation, except for amiodarone. Patients with paroxysmal AF were usually 
discharged without antiarrhythmic drugs. Patients with persistent AF were discharged with 
or without antiarrhythmic drugs according to clinician preference. Patients were scheduled 
for follow-up examinations 3,6, and 12 months after the initial treatment, and rhythm 
monitoring during the follow-up visits was performed by the clinical assessment of AF 
recurrence and Holter monitoring.    
Ablation was deemed successful in the absence of symptomatic or asymptomatic atrial 
tachyarrhythmias lasting more than 30 seconds identified on surface ECG or on Holter 
monitoring, off antiarrhythmic drug therapy. In patients with persistent AF we considered 
the ablation successful in absence of symptomatic or asymptomatic atrial 
tachyarrhythmias regardless of antiarrhythmic drug therapy used. As early relapse of atrial 
tachyarrhythmias within the first 3 months after RF ablation may be a transient 
phenomenon, this transition period was excluded from the final analysis (8). 
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Statistical analysis. Normally distributed continuous variables were expressed as mean 
(±SD) and compared by unpaired Student's t test. Skewed variables were expressed as 
median (25-75 quartiles) and compared by the runk-sum test. Normality was assessed by 
the Shapiro-Wilk test. Categorical variables were presented as counts and percentages, 
and compared by Chi square test (Pearson, Yates or Fisher’s exact test as appropriate). A 
Kaplan-Meier (KM) curve was plotted for the time to first atrial arrhythmia recurrence 
following initial ablation procedure. The probabilities of freedom from atrial arrhythmia 
recurrence at each 3-month follow-up time point post-blanking were presented. 
Differences between the curves were tested for significance by means of the log-rank 
statistics. A p value <0.05 was considered statistically significant. Analysis was performed 
by means of SPSS (version 11.0, SPSS Inc., Chicago, Illinois, USA). 
 
RESULTS 
Study population. One hundred-eighty consecutive patients were included in the study, 
140 (78%) patients had paroxysmal AF, 40 (22%) had persistent AF. Their clinical 
characteristics are showed in Table I. 
Procedural data. Mean overall procedure time was 113±53 min with a mean fluoroscopy 
time of 13.1±8.4 min. Image integration was used in 42/180 (23%) patients. The use of a 
pre-ablation PV imaging related to a significant reduction in fluoroscopy time (from 
14.7±9.7 to 8.7±6.6, p<0.001). Mean ablation time (RF time needed for PV isolation) was 
12.5±5.1 min, 98% of the targeted veins were isolated with a mean of 23.4±6.3 RF pulses 
per patient. In only four (2.2%) patients a single point ablation strategy was required to 
achieve the PV isolation. Intraprocedural early PV reconnection occurred in 187/695 (27%) 
PVs  and all PVs were effectively re-isolated. 
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Follow-up data. During the blanking period 25/140 (18%) patients with paroxysmal AF 
had an atrial arrhythmia recurrence. Among them 5 were atrial tachycardia or atrial flutter 
and the remaining AF episodes.  During the blanking period 4/40 (10%) patients with 
persistent  AF had an atrial arrhythmia recurrence, in all cases an AF episode was 
documented. During a mean follow-up of 13.9 ± 8.2 months 38/140 (27%) patients with 
paroxysmal AF and 12/40 (30%) patients with persistent AF had an atrial arrhythmia 
relapse (p=0.671) (Figure 2). At time of atrial arrhythmias recurrence, 31/40 (78%) patients 
with persistent AF were on antiarrhythmic drugs. Overall 10/50 (20%) patients with atrial 
arrhythmia relapses underwent a second ablation procedure. 
Complications. No stroke/TIA, pericardial effusion, or cardiac tamponade were observed. 
One groin hemathoma and one PV stenosis were reported. Both were conservatively 
treated. 
 
DISCUSSION 
In this multicenter registry, CA of AF aiming at PV isolation by means of an irrigated multi-
electrode RF ablation catheter resulted feasible, achieving a high rate of isolated PVs. In 
addition, procedural and fluoroscopy times were comparable with other techniques. Pre-
ablation imaging allowed reduced fluoroscopy time. The mid-term success rates was 
comparable with other techniques with a low complication rate. 
Procedural data. PV isolation, using an open irrigated catheter, with a point-by-point 
ablation strategy and a circular mapping catheter to validate it, is a well-established 
approach for AF CA (3). However it could be time consuming, often requires long 
fluoroscopy exposure, and the clinical results and complications are still depending on 
center volume and operator experience. To overcome some of these limitations and 
simplify the CA procedure different “one-shot” techniques have been developed (4-7). The 
nMARQTM catheter is a novel multipolar ablation catheter using irrigated RF technology 
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and integration into the CARTO3 system. To date five (7,9-12) single center experiences 
have been reported, documenting the feasibility and acute efficacy of AF ablation by the 
use of nMARQTM. However each of these studies included only a maximum 43 patients. In 
our registry, instead, we collected data on 180 patients from 7 centers. We confirmed the 
high success rate (98%) in achieving PV isolation. Only in four patients an additional 
“point-by-point” ablation was required to achieve complete PV isolation. Our procedure 
and fluoroscopy time were similar to that reported by single centers. Our data were 
gathered as soon as the nMARQTM system became available at each centre, with 
operators using this new technology for the first time. We could suppose that after a 
learning curve and greater experience further reduction in procedure duration and 
fluoroscopy time would become evident. It is well known that PVs anatomy variability is 
remarkable and, due to this, the use of a presized circular multipolar ablation catheter may 
present some limitations. In our cohort we were able to achieve PV isolation in nearly all 
patients, regardless of the PV/left atrium anatomy, however the prior knowledge of the 
anatomy allowed a significant reduction in the fluoroscopy time.  
Safety concerns. Preliminary reports raised concerns about the safety of the nMARQTM 
catheter. Deneke et al (7,13) reported one esophago-pericardial fistula, a high incidence of 
mild thermal esophageal lesions, and an incidence of silent cerebral lesions higher than 
single-tip irrigated RF. However Scaglione et al (12), using a specific and cautious 
procedural workflow, observed the complete absence of periprocedural silent cerebral 
ischemia. In our series no stroke/TIA, pericardial effusion, or cardiac tamponade were 
observed.  Moreover, no phrenic nerve paralysis was observed thus confirming the safety 
profile of this catheter as compared with other “one-shot” devices (e.g. phrenic nerve 
palsies were registered following cryoballoon ablation in the STOP-AF (14) trial in 11.2% 
cases). 
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Although all maneuvers to reduce the risk of PV stenosis, like adjusting the diameter of the 
circular ablation catheter to deliver RF at the antrum of the vein, were followed, in our 
series, a case of PV stenosis was documented.  
Mid-term outcome. Few data are available on the follow-up. In the Scaglione et al (12) 
series 17/25 (68%) patients with paroxysmal AF were free from AF without antiarrhythmic 
drugs at a 6-month follow-up; in the Shin et al (10) series, after 3 months, sinus rhythm 
was stable off antiarrhythmic drugs in 17 of 21 (80.9%) patients; in the Zellerhof et al (11) 
series single and multiple procedure success rates during a mean follow-up of 140+75 
days were 66 and 77%, respectively. In our cohort the freedom of atrial arrhythmias was 
similar at a longer follow-up (13.9 months) and also patients with persistent AF showed a 
recurrence rate of 30%.  
Limitations. Several limitations of our study have to be addressed. The validation of the 
PV isolation is probably the major week point of this technology. We used the signals 
recorded by the nMARQTM catheter to demonstrate the PV entrance block. However 
reliability of local electrograms recorded by the nMARQTM catheter in detecting the PV 
isolation remains to be demonstrated. Rosso et al (9) and Scaglione et al (12) showed that 
the overall concordance between Lasso and nMARQTM signals in demonstrating PV 
isolation ranged from 78 to 92%. Possible explanations may be the difference in 
interelectrode spacing, the electrodes size, and more proximal position in the PVs ostia of 
the nMARQTM, which may influence the endocardial electrograms characteristics. 
Nevertheless, our acute and mid-term outcome can be attributed only to the use of the 
nMARQTM technology because, in our study protocol, the Lasso catheter was not used to 
confirm PV isolation. Second, the length of mean follow-up was a little more than one year. 
A conclusion on long-term success rates is therefore not yet available. Third, this is a 
multicenter study and the ablation strategy (pre-procedural imaging, oral anticoagulant 
management) was not standardized. However, this observational prospective study may 
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provide a representative image of the real-life scenario on the use of nMARQTM for AF 
ablation. The data on the number of electrodes activated during each RF pulse is 
unfortunately not available. Moreover, exit block from the PV was not checked in all 
patients, this could overestimate the rate of effective PV isolation. Finally, we did not 
provide data on asymptomatic cerebral ischemia and esophageal lesions were not 
searched for by endoscopy. Neither a standardized methodology for screening for PV 
stenosis was used, but a routine surveillance took place in each center according to local 
practice. 
 
 
CONCLUSIONS 
Irrigated multi-electrode RF ablation of AF using the nMARQ catheter was feasible and 
effective. We observed an high rate of isolated PVs in an unselected, consecutive cohort 
of patients with paroxysmal and persistent AF. Success rates were comparable with other 
techniques applied in AF ablation with a low complication rate, although severe in one 
patient.  Longer FU and larger, multicenter randomized studies are needed to confirm 
these results. 
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Appendix 
Participating centers: 
Clinica Mediterranea, Napoli (Giuseppe Stabile, Assunta Iuliano, Alfonso Panella); 
Policlinico Casilino, Roma (Leonardo Calò, Gildo De Ruvo, Luigi Sciarra); Ospedale Miulli, 
Acquaviva Delle Fonti (BA) (Massimo Grimaldi); Ospedale San Gerardo, Monza (Giovanni 
Rovaris); Azienda Ospedaliero Universitaria Pisana, Pisa (Ezio Soldati, Maria Grazia 
Bongiorni); Dipartimento di Scienze Mediche, Università di Torino (Matteo Anselmino, 
Federico Ferraris, Fiorenzo Gaita);  Clinica Montevergine, Mercogliano (AV), Italia 
(Francesco Solimene, Vincenzo Schillaci). 
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CLINICAL PERSPECTIVES 
The nMARQTM, irrigated multi-electrode RF ablation catheter, is a safe and effective tool to 
perform AF ablation aiming at PV isolation. We were able to achieve PV isolation in nearly 
all patients, regardless of the PV/left atrium anatomy, however the prior knowledge of the 
anatomy allowed a significant reduction in the fluoroscopy time. Overall procedural and 
fluoroscopy times and mid-term success rate were comparable with other techniques, with 
a low complication rate. 
The use of this “one-shot” tool, as others, might facilitate AF ablation, perhaps overcoming 
the limitation that clinical results and complications of single point technologies are still 
dependent on center volume and operator experience.    
Further and randomized studies are required to compare the safety and the efficacy of this 
catheter with the other single point or single shot technologies. 
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Figure legend. 
Figure 1. Panel A: Endocardial and surface recordings during coronary sinus pacing of 
right inferior pulmonary vein, after radiofrequency delivery and pulmonary vein isolation.  
Panels B: Endocardial and surface recordings during coronary sinus pacing of right inferior 
pulmonary vein before radiofrequency delivery. (arrow= pulmonary vein potentials.  Panel 
C: Postero-anterior view of left atrium CARTO3 reconstruction with nMARQ catheter 
positioned at the ostium of the right inferior pulmonary vein (red dots: radiofrequency 
ablation points). Panel D: Latero-lateral view of left atrium CARTO3 reconstruction. 
Figure 2. Kaplan–Meier estimation of the time to atrial arrhythmia recurrence after the 
blanking period in patients with paroxysmal (PAROX) and persistent (PERS) patients. 
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 Table I. Clinical characteristics of study population 
Mean age (years) 58±10 (range 21-75) 
Male sex 69% 
Left atrium diameter (mm) 46±10 (range 33-73) 
Left atrium volume (ml) 79±26 (range 46-131) 
Left ventricle ejection fraction (%) 59±5 (range 30-70) 
Previous stroke/TIA 6% 
Heart disease 
    Hypertensive  
    Ischemic 
    Valvular 
    Restrictive 
51% 
48% 
4% 
2% 
1% 
Diabetes  4% 
 
